Infectious Disease Advisor news story
Evidence of HIV-1 is uncommon among individuals receiving long-acting cabotegravir (LA CAB) for PrEP, although HIV testing is not consistently documented around injections, according to study results presented at IDWeek 2026, held from October 21 to 24, in Washington, DC.
Researchers evaluated real-world HIV testing, changes in PrEP use, and evidence of HIV-1 among individuals receiving LA CAB in routine clinical practice. The retrospective PrEPFACTS cohort study used data from the Komodo Research Database, extending an earlier analysis to include claims through September 2024.
Read the full news story here.
/Infectious Disease Advisor requires free registration if more than 5 articles are viewed per month/
View all Infectious Disease Advisor reports from IDWeek 2026
Source : Infectious Disease Advisor
Related HIV and Co-Infections News
-
HIV i-Base | 3rd London Chemsex Conference: An expanding network of excellent but under-funded services and an urgent need for data
-
[IDWeek 2026] Healio | Study: Recommending HPV vaccine at age 9 improves uptake
-
[Call to action] AVAC | No time to lose: Reaching at least three million with LEN for PrEP by 2027
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.